Discover practical resources to support you in onboarding and managing patients prescribed VENCLEXTA® (venetoclax).
CLL online training modules
A comprehensive set of online training modules to better understand the mechanism of action and clinical trial outcomes (including key efficacy and safety data) for VENCLEXTA in CLL, as well as practical management considerations for patient onboarding.
Duration: 3 x ~10 minute modules.
AML online training modules
These educational modules can help you learn more about prescribing and managing VENCLEXTA in combination with azacitidine for the treatment of adult patients with newly-diagnosed AML who are ineligible for intensive chemotherapy.1
Duration: 3 x ~10 minute modules.
Nurse onboarding videos
Getting started with VENCLEXTA is a series of five videos designed for nurses describing key considerations for the onboarding process for patients with CLL/SLL prescribed VENCLEXTA. The series also features a number of practical tips for nurses from their peers.
The following educational materials were developed in collaboration with and endorsed by a haematology and oncology clinical nurse consultant steering committee.
Key role of Nurses in VENCLEXTA treatment
NURSE-ENDORSED PATIENT RESOURCES
The following educational materials were developed in collaboration with and endorsed by a haematology and oncology clinical nurse consultant steering committee.
End of treatment brochure (1L or R/R CLL)
Share this resource with your patients with CLL to help explain why their treatment is of fixed duration and what happens once treatment stops.
Mechanism of action video
Share this video with your patients to help explain how VENCLEXTA works, and to reinforce the importance of hydration and blood tests during treatment onboarding. (4 min 35 sec)
Patient Diary (1L or R/R CLL)
A short booklet designed to help patients understand their VENCLEXTA medication schedule, how to take their treatment, and answer some frequently asked questions. Includes a treatment diary for patients to fill in during the 5-week ramp-up period.
Digital patient diary (1L or R/R CLL)
This digital version of the patient diary is intended to be completed by a healthcare professional to be provided to patients. This tool helps patients understand their VENCLEXTA medication schedule and when their appointments and blood tests are scheduled, it answers frequently asked questions and includes a treatment diary for patients to fill in during the 5-week ramp-up period.
OTHER PATIENT RESOURCES
Patient information brochure for VENCLEXTA + obinutuzumab treatment (1L CLL)
Share this resource with your 1L CLL patients to help support them during VENCLEXTA + obinutuzumab treatment.
Patient information brochure for VENCLEXTA + rituximab treatment (R/R CLL)
Download this resource to help educate and support your R/R CLL patients starting VENCLEXTA + rituximab treatment.
VENCLEXTA CONSUMER MEDICINES INFORMATION (CMI)
Download the CMI to provide your patients more information about VENCLEXTA.
Contact
Discover more about how we can help you in your practice.
PBS Information
Venclexta: VENCLEXTA (venetoclax) in combination with rituximab is PBS listed for relapsed or refractory chronic lymphocytic leukaemia (CLL). VENCLEXTA in combination with obinutuzumab is PBS listed for first line treatment of CLL or small lymphocytic lymphoma (SLL). VENCLEXTA in combination with azacitidine is PBS listed for treatment of acute myeloid leukaemia (AML). General Schedule listing. Authority required (telephone). Refer to PBS schedule for full authority information. VENCLEXTA monotherapy is not listed on the PBS. VENCLEXTA in combination with low-dose cytarabine is not listed on the PBS for treatment of AML.
Please review the full Product Information (PI) before prescribing, available below.
1L: first-line. CLL: chronic lymphocytic leukemia. CMI: Consumer Medicines Information. HCPs: healthcare professionals. R/R CLL: relapsed or refractory CLL. TLS: tumour lysis syndrome.
AU-VENC-200118 Last revised October 2022